13492-01-8
基本信息
硫酸反苯环丙胺 标准品
反-2-苯基环丙基胺半硫酸盐
反式-2-苯基环丙胺 半硫酸盐
TRANYLCYPROMINE硫酸盐
tranylcyprominesulfate
tranylcyprominesulphate
phenylcycloprominesulfate
TRANYLCYPROMINE HEMISULFATE
Tranylcypromine Sulfate (125 mg)
TRANYLCYPROMINE HEMISULFATE SALT
Tranylcypromine Sulfate (1672905)
1-amino-2-phenylcyclopropanesulfate
trans,d,l-2-phenylcyclopropylaminesulfate
物理化学性质
| 储存条件 | 2-8°C |
| 溶解度 | 易溶于水；极微溶于乙醇(96%)和乙醚。 |
| 形态 | 白色固体。 |
| 颜色 | 白色 |
| 水溶解性 | water: 0.0333g/mL, clear to slightly hazy, colorless to faintly yellow |
| 稳定性 | 自购买之日起 1 年内保持稳定。蒸馏水溶液可在 -20° 下保存长达 3 个月。 |
| InChI | 1S/2C9H11N.H2O4S/c2*10-9-6-8(9)7-4-2-1-3-5-7;1-5(2,3)4/h2*1-5,8-9H,6,10H2;(H2,1,2,3,4)/t2*8-,9+;/m11./s1 |
| InChIKey | BKPRVQDIOGQWTG-FKXFVUDVSA-N |
| SMILES | OS(O)(=O)=O.N[C@H]1C[C@@H]1c2ccccc2.N[C@H]3C[C@@H]3c4ccccc4 |
安全数据
| 危险性符号(GHS) |  GHS06 |
| 警示词 | 危险 |
| 危险性描述 | H300-H311+H331 |
| 防范说明 | P261-P264-P280-P301+P310-P302+P352+P312-P304+P340+P311 |
| 危险品标志 | T |
| 危险类别码 | 23/24/25 |
| 安全说明 | 36/37/39-45 |
| 危险品运输编号 | UN 2811 6.1/PG 2 |
| WGK Germany | 3 |
| RTECS号 | GZ2625000 |
| 危险等级 | 6.1(b) |
| 包装类别 | III |
| 海关编码 | 2921490002 |
| 存储类别 | 6.1A - Combustible acute toxic Cat. 1 and 2 very toxic hazardous materials |
| 危险性类别 | Acute Tox. 2 Oral Acute Tox. 3 Dermal Acute Tox. 3 Inhalation |
反苯环丙胺半硫酸盐价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-B1496R | 反苯环丙胺半硫酸盐 Tranylcypromine hemisulfate (Standard) | 13492-01-8 | 10 mg | 360元 |
| 2026/09/15 | HY-B1496R | 反苯环丙胺半硫酸盐 Tranylcypromine hemisulfate (Standard) | 13492-01-8 | 25 mg | 660元 |
| 2026/09/15 | HY-B1496R | 反苯环丙胺半硫酸盐 Tranylcypromine hemisulfate (Standard) | 13492-01-8 | 50 mg | 1000元 |
常见问题列表
Tranylcypromine (10 nM to 10 µM) exerts neuroprotective effects against toxicity induced by human Aβ(1-42) oligomers independently from the presence of glial cells. Tranylcypromine (100 μM) significantly protects RGCs from glutamate neurotoxicity-induced apoptosis as well as apoptosis induced by oxidative stress. Tranylcypromine promotes mitogen-activated protein kinase 12 (p38 MAPKγ) expression under conditions of glutamate (Glu)-induced stress. Besides, tranylcypromine contributes to RGC survival via alterations of p38 MAPKγ activity.
Tranylcypromine treatment significantly and substantially reduces the lesion size and improves generalized hyperalgesia in a dose-dependent fashion in mice with induced endometriosis. In addition, tranylcypromine treatment results in reduced immunoreactivity to biomarkers of proliferation, angiogenesis, and H3K4 methylation, leading to arrested EMT and lesion growth. Tranylcypromine (500 mM) injection exerts neuroprotective effects within intracellular apoptotic signaling pathways and suppresses morphologic changes in the retina of the rat, suppresses caspase 3 activity and recovers p38 MAPKγ expression in the retina after NMDA-induced injury, and enhances RGC survival after retinal injury via the attenuation of NMDA neurotoxicity. Tranylcypromine (10 µg/g) causes an approximate and significant doubling of labeled cells in the combined brain regions examined, as detected by BrdU immunohistochemistry. Tranylcypromine causes the greatest increase in cell proliferation in the cerebellum.